NSE: LALPATHLAB · BSE: 539524 · ISIN INE600L01024
Dr. Lal Pathlabs Limited stock analysis
Dr. Lal Pathlabs Limited ranks #89 in the TickerSutra evidence-ranked universe with a score of 73/100 and 95% data confidence. The latest captured fundamentals show ROCE of 28.0%, quarterly sales growth of 19.1% and quarterly profit growth of 28.0%.Watchlist candidate
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 28%
- Low debt/equity of 0.08×
- Strong CFO/EBITDA of 0.81×
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹2,087cr | ₹561cr | ₹350cr | 27.0% |
| 2023 | ₹2,017cr | ₹490cr | ₹241cr | 24.0% |
| 2024 | ₹2,227cr | ₹609cr | ₹362cr | 27.0% |
| 2025 | ₹2,461cr | ₹698cr | ₹492cr | 28.0% |
| 2026 | ₹2,763cr | ₹783cr | ₹510cr | 28.0% |
| TTM | ₹2,891cr | ₹838cr | ₹546cr | 29.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL
RoutineDr. Lal PathLabs Ltd - 539524 - Board Meeting Intimation for The Quarter And Half Year Ending On September 30, 2026BSE · 25 Sept 2026Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the un-audited (Standalone ....
RoutineTrading WindowBSE · 25 Sept 2026Dr. Lal Path Labs Ltd. has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
MANAGEMENT COMMENTARY
Signals from filed documents
The incorporation of our wholly owned subsidiary in Dubai marks a considered first step in extending our diagnostic expertise outside India, building on our existing presence in Nepal and Bangladesh. In parallel, the broader healthcare ecosystem is expanding, with hospitals across the country adding new capacity and capability. This tailwind is opening up deeper integration, stronger clinical partnerships, and greate
• Further, I am happy to share that the Board of Directors have declared an interim dividend of 50% (i.e. We remain confident in our outlook and our ability to deliver sustainable and profitable growth, while continuing to uphold our commitment to providing reliable and high-quality diagnostics. With this, I conclude my opening remarks, and I would now request the moderator to open the forum for Q&A.
So just coming back to the CGHS price hike, I understand that the top line kind of benefited from this, but in terms of margins, should we also kind of factor in because your cost would broadly be remaining similar on the fixed part? So , was there some benefit on the margin side as well coming in from the higher price realization at CGHS and will that also kind of continue for the next 2-3 quarters? So, there will b
Second question is on the acquisitions that we have made in the current quarter. First on Neuome Technologies , is this, if I understand this correctly, is this sort of venturing into allied healthcare services or will this investment be used for internal consumption or a backward integration kind of purposes? Page 9 of 20 Shankha Banerjee: Neuome Technologies is a startup which is working on quite some interesting i
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…